Form 144 Hims & Hers Health, Inc. Filed by: Boughton Soleil
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/8/2026
- Wall St turns lower as crude spikes, chip stocks weigh
- Oil jumps 5%, then pares gains after Trump says no attack on Iran this month
- Chipotle, Starbucks shares volatile after report of potential takeover
- Why Citi says the Fed could be setting up for a dovish surprise
- Alphabet shares rise as Google pushes Gemini deeper into enterprise AI
- Anthropic launches Claude Haiku 5.5 with tiered pricing structure
- CoreWeave stock drops on dilution fears and debt concerns
- Sportradar to sell Synergy Sports coaching unit for $170M
- Rezolve AI (RZLV) Reiterated at Overweight by Cantor Fitzgerald on Positioning as Key Component in E-Commerce Stack
- Wall Street ends lower, off record highs, as Treasury yields climb
Hims and Hers (HIMS) PT Raised to $24 at Canaccord Genuity
May 22, 2024 5:29 AM EDTCanaccord Genuity analyst Maria Ripps raised the price target on Hims and Hers (NYSE: HIMS) to $24.00 (from $20.00) while maintaining a Buy rating.
The analyst comments "On Monday, 5/20, Hims & Hers announced the addition of GLP-1 treatment to its portfolio of weight loss solutions, with prices... More



